RxDoctor Payments Data

Charalambos Solomides, MD

Clinical Pathology/Laboratory Medicine · Philadelphia, PANPI 1275521353

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (44.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Roche Diagnostics Corporation accounts for 74.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $15,453 and has fallen 85.3% since, to $2,270 in 2025. Among clinical pathology/laboratory medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,695in general payments, 2019–2025

Across 22 payments — averaging $940.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Roche Diagnostics Corporation$15K
  • AstraZeneca$2K
  • Astrazeneca UK Limited$2K
  • AbbVie$500
  • Ventana Medical Systems, Inc.$92
  • Caris MPI, Inc.$80
$36,346in research payments, 2019–2025

Across 4 payments — averaging $9086.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ventana Medical Systems, Inc.$36K

What the payments were for

  • Consulting fees$8,11039%
  • Speaking & faculty fees$9,20044%
  • Travel & lodging$2,51112%
  • Food & beverage$8754%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,695 in reported general payments places this provider in the 95th percentile of 44 clinical pathology/laboratory medicine providers in Pennsylvania.

See all clinical pathology/laboratory medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$54,754
Medicare patients
308
Services billed
1,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical pathology/laboratory medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →